Navamedic ASA's (OB:NAVA) Profit Outlook

Navamedic ASA (OB:NAVA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The kr371m market-cap company posted a loss in its most recent financial year of kr24m and a latest trailing-twelve-month loss of kr23m shrinking the gap between loss and breakeven. Many investors are wondering about the rate at which Navamedic will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

According to the 2 industry analysts covering Navamedic, the consensus is that breakeven is near. They expect the company to post a final loss in 2026, before turning a profit of kr7.7m in 2027. So, the company is predicted to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 118%, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Navamedic's growth isn’t the focus of this broad overview, however, bear in mind that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

See our latest analysis for Navamedic

One thing we would like to bring into light with Navamedic is its relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in Navamedic's case is 59%. Note that a higher debt obligation increases the risk in investing in the loss-making company.

Next Steps:

There are too many aspects of Navamedic to cover in one brief article, but the key fundamentals for the company can all be found in one place – Navamedic's company page on Simply Wall St. We've also put together a list of relevant factors you should further examine:

1. Valuation: What is Navamedic worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Navamedic is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Navamedic’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.